This is a preprint.
Maternal-fetal interfaces transcriptome changes associated with placental insufficiency and a novel gene therapy intervention
- PMID: 38895421
- PMCID: PMC11185673
- DOI: 10.1101/2024.06.05.597595
Maternal-fetal interfaces transcriptome changes associated with placental insufficiency and a novel gene therapy intervention
Update in
-
Maternal-fetal interfaces transcriptome changes associated with placental insufficiency and a novel gene therapy intervention.Physiol Genomics. 2025 Jan 1;57(1):8-15. doi: 10.1152/physiolgenomics.00131.2024. Epub 2024 Oct 7. Physiol Genomics. 2025. PMID: 39374081 Free PMC article.
Abstract
The etiology of fetal growth restriction (FGR) is multifactorial, although many cases often involve placental insufficiency. Placental insufficiency is associated with inadequate trophoblast invasion resulting in high resistance to blood flow, decreased availability of nutrients, and increased hypoxia. We have developed a non-viral, polymer-based nanoparticle that facilitates delivery and transient gene expression of human insulin-like 1 growth factor ( hIGF1 ) in placental trophoblast for the treatment of placenta insufficiency and FGR. Using the established guinea pig maternal nutrient restriction (MNR) model of placental insufficiency and FGR, the aim of the study was to identify novel pathways in the sub-placenta/decidua that provide insight into the underlying mechanism driving placental insufficiency, and may be corrected with hIGF1 nanoparticle treatment. Pregnant guinea pigs underwent ultrasound-guided sham or hIGF1 nanoparticle treatment at mid-pregnancy, and sub-placenta/decidua tissue was collected 5 days later. Transcriptome analysis was performed using RNA Sequencing on the Illumina platform. The MNR sub-placenta/decidua demonstrated fewer maternal spiral arteries lined by trophoblast, shallower trophoblast invasion and downregulation of genelists involved in the regulation of cell migration. hIGF1 nanoparticle treatment resulted in marked changes to transporter activity in the MNR + hIGF1 sub-placenta/decidua when compared to sham MNR. Under normal growth conditions however, hIGF1 nanoparticle treatment decreased genelists enriched for kinase signaling pathways and increased genelists enriched for proteolysis indicative of homeostasis. Overall, this study identified changes to the sub-placenta/decidua transcriptome that likely result in inadequate trophoblast invasion and increases our understanding of pathways that hIGF1 nanoparticle treatment acts on in order to restore or maintain appropriate placenta function.
Similar articles
-
Maternal-fetal interfaces transcriptome changes associated with placental insufficiency and a novel gene therapy intervention.Physiol Genomics. 2025 Jan 1;57(1):8-15. doi: 10.1152/physiolgenomics.00131.2024. Epub 2024 Oct 7. Physiol Genomics. 2025. PMID: 39374081 Free PMC article.
-
Mid-Pregnancy Placental Transcriptome in a Model of Placental Insufficiency with and without Novel Intervention.Reprod Sci. 2025 Feb;32(2):435-443. doi: 10.1007/s43032-024-01769-4. Epub 2024 Dec 20. Reprod Sci. 2025. PMID: 39707140 Free PMC article.
-
Mid-pregnancy placental transcriptome in a model of placental insufficiency with and without novel intervention.bioRxiv [Preprint]. 2024 Jun 9:2024.06.05.597621. doi: 10.1101/2024.06.05.597621. bioRxiv. 2024. Update in: Reprod Sci. 2025 Feb;32(2):435-443. doi: 10.1007/s43032-024-01769-4. PMID: 38895312 Free PMC article. Updated. Preprint.
-
An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array.Am J Obstet Gynecol. 2022 Feb;226(2S):S963-S972. doi: 10.1016/j.ajog.2020.10.023. Epub 2021 Mar 9. Am J Obstet Gynecol. 2022. PMID: 33712272 Review.
-
Expert review: preeclampsia Type I and Type II.Am J Obstet Gynecol MFM. 2023 Dec;5(12):101203. doi: 10.1016/j.ajogmf.2023.101203. Epub 2023 Oct 21. Am J Obstet Gynecol MFM. 2023. PMID: 37871693 Review.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous